〔1〕 CHAPMAN A, MULRENNAN S, LADD B, et al. Population Based Epidemiology and Prognosis of Meso-thelioma in Leeds,UK〔J〕.Thorax,2008,63(5):435-439.
〔2〕 MAO W, ZHANG X, GUO Z, et al. Association of Asbestos Exposure with Malignant Mesothelioma Inci-dence in Eastern China〔J〕.JAMA Oncol,2017,3(4):562-564.
〔3〕 王凯歌,李为民.恶性胸膜间皮瘤的研究和管理:英国胸科协会指南解读〔J〕. 中华肺部疾病杂志(电子版), 2020,
13(2):265-268.
〔4〕 常浩,余宗艳,王启明,等.120例恶性胸膜间皮瘤的临床特征及诊断分析〔J〕.肿瘤,2020,40(3):199-205.
〔5〕 MUTTI L, PEIKERT T, ROBINSON B W S, et al. Scientific Advances and New Frontiers in Mesothelioma Therapeutics〔J〕. J Thorac Oncol,2018,13(9):1269-1283.
〔6〕 徐雷,梁桐,夏雨,等. THBS2在常见肿瘤中临床意义的研究进展〔J〕. 老年医学研究, 2020,1(2):54-57.
〔7〕 CALABRO N E, KRISTOFIK N J, KYRIAKIDES T R. Thrombospondin-2 and Extracellular Matrix Assembly〔J〕. Biochim et Biophys Acta, 2014, 1840(8): 2396-2402.
〔8〕 BORNSTEIN P. Thrombospondins as Matricellular Modu-lators of Cell Function〔J〕. J Clin Invest,2001,107(8):929-934.
〔9〕 STENINA O I, TOPOL E J, PLOW E F. Thrombospon-dins, Their Polymorphisms, and Cardiovascular Disease〔J〕. Arterioscler Thromb Vasc Biol,2007,27(9):1886-1894.
〔10〕 GORDON G J, ROCKWELL G N, JENSEN R V, et al. Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling〔J〕. Am J Pathol, 2005,166(6):1827-1840.
〔11〕 KIM M K, KIM H W, JANG M, et al. LOX Family and ZFPM2 as Novel Diagnostic Biomarkers for Malignant Pleural Mesothelioma〔J〕. Biomark Res,2020,8(1):1-7.
〔12〕 范冲冲, 乔建瓯. 血小板反应蛋白2与肿瘤〔J〕. 国际肿瘤学杂志,2021,48(3):164-166.
〔13〕 WENG T Y, WANG C Y, HUNG Y H, et al. Differential Expression Pattern of THBS1 and THBS2 in Lung Cancer: Clinical Outcome and a Systematic-Analysis of Microarray Databases〔J〕. PLoS One, 2016, 11(8): e0161007.
〔14〕 KIM J, BAMLET W R, OBERG A L, et al. Detection of Early Pancreatic Ductal Adenocarcinoma with Thrombos-pondin-2 and CA19-9 Blood Markers〔J〕. Sci Transl Med,2017,9(398):eaah5583.
〔15〕 杨柳, 罗黔. 胰腺癌组织高表达血小板反应蛋白2的预后意义及其对癌细胞增殖和迁移的影响〔J〕. 中国肿瘤生物治疗杂志, 2019,26(2):206-212.
〔16〕 WANG X, ZHANG L, LI H, et al. THBS2 Is a Potential Prognostic Biomarker in Colorectal Cancer〔J〕. Sci Rep, 2016,6:33366.
〔17〕 SUN R, WU J, CHEN Y, et al. Down Regulation of Thrombospondin2 Predicts Poor Prognosis in Patients with Gastric Cancer〔J〕. Mol Cancer,2014,13:225.
〔18〕 孙若川,李永翔. THBS2在胃癌组织中的表达与预后的关系〔J〕. 安徽医科大学学报, 2014,49(7):995-999.
〔19〕 吴湘光,魏文斐,梁莉,等. THBS2在宫颈癌中的表达及功能研究〔J〕. 现代妇产科进展,2017,26(12):889-892.
〔20〕 KOCH M, HUSSEIN F, WOESTE A, et al. CD36-Mediated Activation of Endothelial Cell Apoptosis by an N-Terminal Recombinant Fragment of Thrombospondin-2 Inhibits Breast Cancer Growth and Metastasis in vivo〔J〕. Breast Cancer Res Treat,2011,128(2):337-346.
〔21〕 SCHULTE J J, HUSAIN A N. Update on the Pathologic Diagnosis of Malignant Mesothelioma〔J〕. Transl Lung Cancer Res,2020,9(3):917-923.
〔22〕 BEASLEY M B, GALATEAU-SALLE F, DACIC S. Pleural Mesothelioma Classification Update〔J〕. Virchows Arch,2021,478(1):59-72.
|